At a glance
ClinicalIndex Comparison RecordPhase 2Active· 198 enrolled
Drug / intervention
BL-B01D1 +1 moredrug
Likely dose
Osimertinib Mesylate Tablets 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 and Osimertinib Mesylate Tablets for Non-small Cell Lung Cancer. Active but no longer recruiting, targeting 198 participants across 1 site.
Detailed Summary
A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Active
2024202520262027
First PostedMay 2023
Enrollment StartJul 2023
TodayJul 2026
Primary CompletionJul 2027
First PostedMay 30, 2023
Enrollment StartJul 19, 2023
Primary CompletionJul 1, 2027
TodayJul 1, 2026
Enrollment to primary: 3.9 yearsPosted 3.1 years agoPrimary completion in 1 year
Interventions
BL-B01D1drug
Administration by intravenous infusion
Osimertinib Mesylate Tabletsdrug
Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.